Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 162

Sort by

Sort Order Select

Journal Articles

Retrospective, Multi-Center Analysis of Ruxolitinib Tapering after Successful Treatment of Steroid Refractory Chronic Graft Versus Host Disease

Daniel Levin, Kareem Jamani, Swe Mar Linn, Benoit Yu, Arjun D. Law, Rajat Kumar, Christopher Lemieux, Mohamed Elemary, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 4934.

https://doi.org/10.1182/blood-2023-188204

Published: 2023

Journal Articles

Is Allogeneic Hematopoietic Stem Cell Transplant (HCT) in First Remission Beneficial to Acute Myeloid Leukemia (AML) Patients with Isocitrate Dehydrogenase(IDH) Mutations?

Ayman Sayyed, Taehyung Simon Kim, Silvia Park, Jae-Sook Ahn, Aly Karsan, Marie-France Gagnon, Julie Bergeron, Hyeoung-Joon Kim, Heeje Kim, David Sanford, Andre C. Schuh, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 4960.

https://doi.org/10.1182/blood-2023-191113

Published: 2023

Journal Articles

Prospective Assessment of Co-Morbidities and Framingham Risk Score in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients and Its Impact on Clinical Outcomes Following Frontline TKI Therapy: Toronto CML Genomic Alliance in Greater Toronto Area & Ontario (TCGA-GTA)

May Chiu, Gopila Gupta, Maria Agustina Perusini, Eshrak Al-Shaibani, Jenny Ho, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 1810.

https://doi.org/10.1182/blood-2023-185370

Published: 2023

Journal Articles

The Presence of Somatic Mutation in Donor Does Not Affect Long-Term Outcomes in 339 Patients Following Allogeneic Hematopoietic Stem Cell Transplantation Using Uniform Fludarabine/Busulfan Myeloablative Conditioning and Cyclosporine/Methotrexate and ATG Gvhd Prophylaxis

Ayman Sayyed, Hyewon Lee, Taehyung Simon Kim, Jaeyoon John Kim, Danielle Pyne, Nathali Kaushansky, Yardena Brilon, Noa Chapal-Ilani, Tamir Biezuner, Liran I. Shlush, Jan Storek, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 2207.

https://doi.org/10.1182/blood-2023-191191

Published: 2023

Journal Articles

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

Josephine Anne Lucero, Aniket Bankar, Marta Beata Davidson, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Dawn C. Maze, Karen Yee, Mark D. Minden, Steven M. Chan, Jonas Mattsson, Rajat Kumar, Vikas Gupta, Jose-Mario Capo-Chichi, Tracy Stockley, Hassan Sibai, Anne Maria Tierens, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 1595.

https://doi.org/10.1182/blood-2023-190694

Published: 2023

Journal Articles

New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison

Gopila Gupta, May Chiu, Eshrak Al-Shaibani, Maria Agustina Perusini, Josephine Lucero, Daniela Zackova, Ivana Jeziskova, Anezka Kvetkova, Tomas Jurcek, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Jiri Mayer, Jessie Medeiros, Sagi Abelson, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 4531.

https://doi.org/10.1182/blood-2023-189827

Published: 2023

Journal Articles

Acute Myeloid Leukemia (AML) Patients with Myelodysplasia (MDS) Related-Gene Mutations in First Complete Remission (CR1) Found to Have Benefit from Allogeneic Hematopoietic Stem Cell Transplant (HCT)

Ayman Sayyed, Taehyung Simon Kim, Silvia Park, Jae-Sook Ahn, Aly Karsan, Marie-France Gagnon, Julie Bergeron, Hee-Je Kim, Hyeoung-Joon Kim, David Sanford, Andre C. Schuh, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 4954.

https://doi.org/10.1182/blood-2023-191011

Published: 2023

Journal Articles

The Presence of Somatic Mutations on Specific Pathways Such As Chromatin Modifier, Spliceosome, and Myeloid Transcription Factor at Diagnosis Was Found to Have Benefit from Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in 1,228 Patients with Acute Myeloid Leukemia in First Complete Remission (CR1)

Ayman Sayyed, Taehyung Simon Kim, Silvia Park, Jae-Sook Ahn, Aly Karsan, Marie-France Gagnon, Julie Bergeron, Hyeoung-Joon Kim, Heeje Kim, David Sanford, Andre C. Schuh, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 4949.

https://doi.org/10.1182/blood-2023-190545

Published: 2023

Journal Articles

Use of Pre-Transplant Minicog Cognitive Impairment Screening and Validation of Frailty and Functionality Assessment Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Tommy Alfaro, Maria Queralt Salas, Eshetu Atenafu, Ora Bascom, Leeann Wilson, Carol Chen, Arjun D. Law, Armin Gerbitz, Auro Viswabandya, Fotios Michelis, Jeffrey H. Lipton, Wilson Lam, Igor Novitzky-Basso, Dennis (Dong Hwan) Dong Hwan Kim, Jonas Mattsson, Ivan Pasic, Rajat Kumar

Blood (2023) 142 (Supplement 1): 5094.

https://doi.org/10.1182/blood-2023-191009

Published: 2023

Journal Articles

Presence of Recurrent Somatic Mutations in Mesenchymal Stromal Cell Fractions Isolated from Acute Myeloid Leukemia As an Evidence of Clonality

Muzaffar Bhatti, Taehyung Kim, Jenny Warrington, Amirthagowri Ambalavanan, Sarah Zarabi, Anthea Travas, Jaeyoon John Kim, Danielle Pyne, Troy Ketela, Andrea Arruda, Mark D. Minden, Armand Keating, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 6042.

https://doi.org/10.1182/blood-2023-185149

Published: 2023

Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Blood (2023) 142 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2023-186854

Published: 2023

Journal Articles

Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission

Blood (2023) 142 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2023-189797

Published: 2023

Journal Articles

Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy

Maria Agustina Perusini, Camille Kockerols, Daniela Žáčková, Franck E. Nicolini, Fausto Castagnetti, Carolina Pavlovsky, Massimo Breccia, Delphine Rea, Carmen Fava, Mary Lynn Savoie, Christophe Bouvier, Petra Čičátková, Julien Bollard, Swe Mar Linn, Gopila Gupta, Emilia Scalzulli, Jiří Mayer, Peter E Westerweel, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 6360.

https://doi.org/10.1182/blood-2023-190293

Published: 2023

Journal Articles

Multiparameter Flow Cytometry-Based Residual Disease Analysis Identifies Intermediate-Risk AML Patients Who May Benefit from Allogeneic Hematopoietic Stem Cell Transplantation

Josephine Anne Lucero, Anne Tierens, Muhned Alhumaid, Jose-Mario Capo-Chichi, Tracy L. Stockley, Vikas Gupta, Steven M. Chan, Andre C. Schuh, Mark D. Minden, Jonas Mattsson, Rajat Kumar, Hassan Sibai, Dennis Dong Hwan Kim

Blood (2022) 140 (Supplement 1): 11797–11798.

https://doi.org/10.1182/blood-2022-168260

Published: 2022

Journal Articles

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2 nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Blood (2022) 140 (Supplement 1): 6774–6775.

https://doi.org/10.1182/blood-2022-168228

Published: 2022

Journal Articles

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

Fatima M Khadadah, Claire Andrews, Eshetu G. Atenafu, Andre C. Schuh, Dawn Maze, Karen Yee, Osamah Jamal S. Jarallah, Mark D. Minden, Aaron D. Schimmer, Steven M. Chan, Vikas Gupta, Dennis Dong Hwan Kim, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3169–3171.

https://doi.org/10.1182/blood-2022-169342

Published: 2022

Journal Articles

Ptcy-ATG-CSA Vs. ATG-MMF-CSA for Gvhd Prevention for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

María Queralt Salas, Abel Santos Carreira, Eshetu G. Atenafu, Arjun D. Law, Wilson Lam, Ivan Pasic, Carol Chen, Dennis Dong Hwan Kim, Fotios V. Michelis, Armin Gerbitz, Jeffrey H. Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya

Blood (2022) 140 (Supplement 1): 4878–4879.

https://doi.org/10.1182/blood-2022-170142

Published: 2022

Journal Articles

ATG-Ptcy-CSA for Gvhd Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults with Hematological Malignancies

Maria Queralt Salas, Abel Santos Carreira, Eshetu G. Atenafu, Tommy Alfaro Moya, Arjun D. Law, Wilson Lam, Ivan Pasic, Carol Chen, Dennis Dong Hwan Kim, Fotios V. Michelis, Armin Gerbitz, Jeffrey H. Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya

Blood (2022) 140 (Supplement 1): 7625–7627.

https://doi.org/10.1182/blood-2022-170267

Published: 2022

Journal Articles

In Vitro Evidence of Double Blockade of Asciminib with Reduced Dose of ATP-Binding Pocket Inhibitors in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation

Ho-Jae Han, Hyeok-Jae Jang, Youngseok Yoo, Taehyung Simon Kim, Jong-Won Kim, Dennis Dong Hwan Kim

Blood (2022) 140 (Supplement 1): 9588–9589.

https://doi.org/10.1182/blood-2022-165593

Published: 2022

Journal Articles

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Maria Agustina Perusini, Eshetu G. Atenafu, Donna L. Forrest, Bence-Bruckler Isabelle, Lynn Savoie, Mary-Margaret Keating, Lambert Busque, Robert Delage, Anargyros Xenocostas, Elena Liew, Pierre Laneuville, Kristjan Paulson, Tracy L. Stockley, Jeffrey H. Lipton, Brian Leber, Dennis Dong Hwan Kim

Blood (2022) 140 (Supplement 1): 6778–6779.

https://doi.org/10.1182/blood-2022-167581

Published: 2022

NARROW

Retrospective, Multi-Center Analysis of Ruxolitinib Tapering after Successful Treatment of Steroid Refractory Chronic Graft Versus Host Disease

Is Allogeneic Hematopoietic Stem Cell Transplant (HCT) in First Remission Beneficial to Acute Myeloid Leukemia (AML) Patients with Isocitrate Dehydrogenase(IDH) Mutations?

Prospective Assessment of Co-Morbidities and Framingham Risk Score in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients and Its Impact on Clinical Outcomes Following Frontline TKI Therapy: Toronto CML Genomic Alliance in Greater Toronto Area & Ontario (TCGA-GTA)

The Presence of Somatic Mutation in Donor Does Not Affect Long-Term Outcomes in 339 Patients Following Allogeneic Hematopoietic Stem Cell Transplantation Using Uniform Fludarabine/Busulfan Myeloablative Conditioning and Cyclosporine/Methotrexate and ATG Gvhd Prophylaxis

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison

Acute Myeloid Leukemia (AML) Patients with Myelodysplasia (MDS) Related-Gene Mutations in First Complete Remission (CR1) Found to Have Benefit from Allogeneic Hematopoietic Stem Cell Transplant (HCT)

Use of Pre-Transplant Minicog Cognitive Impairment Screening and Validation of Frailty and Functionality Assessment Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Presence of Recurrent Somatic Mutations in Mesenchymal Stromal Cell Fractions Isolated from Acute Myeloid Leukemia As an Evidence of Clonality

Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission

Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy

Multiparameter Flow Cytometry-Based Residual Disease Analysis Identifies Intermediate-Risk AML Patients Who May Benefit from Allogeneic Hematopoietic Stem Cell Transplantation

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2 nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

Ptcy-ATG-CSA Vs. ATG-MMF-CSA for Gvhd Prevention for 10/10 HLA Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

ATG-Ptcy-CSA for Gvhd Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults with Hematological Malignancies

In Vitro Evidence of Double Blockade of Asciminib with Reduced Dose of ATP-Binding Pocket Inhibitors in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation

Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only